October 25, 2016 1:35 AM ET


Company Overview of Agendia N.V.

Company Overview

Agendia N.V. offers discovery, development, marketing, and commercialization of genomic-based diagnostic products to improve the quality of life for cancer patients by providing healthcare professionals with critical information to enable personalized treatment. It offers Symphony suite of molecular diagnostic breast cancer tests, such as TargetPrint, a microarray-based gene expression assay, which offers a quantitative assessment of the patient’s level of estrogen receptor, progesterone receptor, and HER2/neu gene within breast cancer tumor; and MammaPrint, a IVDMIA gene expression breast cancer assay that provides physicians with the ability to identify which early-stage breast cancer pati...

Science Park 406

Amsterdam,  1098XH


Founded in 2003

100 Employees


31 20 462 1500


31 20 462 1505

Key Executives for Agendia N.V.

Chief Executive Officer
Co-Founder and Chief Research Officer
Age: 59
Co-Founder and Chief Scientific Officer
Age: 63
Chief Financial Officer
Chief Medical Officer and Member of Medical Advisory Board
Compensation as of Fiscal Year 2016.

Agendia N.V. Key Developments

Agendia N.V. Announces Executive Changes

Agendia N.V., announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. He succeeds Jan Egberts, M.D., who took on the position of CEO last October on an interim basis. Straley brings more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services. Most recently he served as President, Anatomical Pathology of ThermoFisher Scientific (Waltham, Mass.). Prior to this position he was President and CEO of Metamark Genetics (Cambridge, Mass.), a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients.

Agendia’s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference

Agendia announced new data from an ongoing study indicates the BluePrint® functional molecular subtyping assay more accurately identifies molecular subgroups and may be a better guide for neoadjuvant treatment than standard, local IHC/FISH assays. The aim of the prospective NBRST study is to compare functional molecular subtyping by BluePrint/MammaPrint® to conventional local IHC/FISH subtyping to predict chemosensitivity as defined by pathologic complete response (pCR). Agendia’s BluePrint 80-gene Molecular Subtyping Assay is the most widely available test providing the functional molecular subtype of a woman’s breast cancer. BluePrint is performed on formalin-fixed paraffin-embedded (FFPE) tissue and is part of Agendia’s suite of breast cancer assays that also includes the MammaPrint 70-gene Risk of Recurrence assay, which recently received FDA 510(k) clearance for use in FFPE tissue samples. MammaPrint was the first breast cancer risk of recurrence multi-gene assay to receive FDA 510(k) clearance. With the most recent clearance, Agendia now has six FDA clearances in its breast cancer portfolio.

Agendia Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test

Agendia announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's MammaPrint® breast cancer recurrence test in FFPE (formalin-fixed paraffin embedded) tissue. The MammaPrint FFPE test utilizes the same 70 genes and proprietary algorithm as the previously cleared MammaPrint Fresh, the first multi-gene medical device to ever receive a 510(k) FDA clearance. Due to the larger panel of genes than any other commercially available test, both tests provide an unambiguous result of Low vs. High risk for recurrence of a patient s breast cancer. This capability surpasses all other commercially available tests because it applies across all age groups, and is not restricted by estrogen or HER 2 receptor status. This additional insight about the cancer's biology enables physicians to appropriately choose the best treatment for their patients. MammaPrint FFPE changes the conversation between physicians and patients at that critical point where treatment decisions are being made. The test result eliminates the ambiguity of the Intermediate result seen in other test platforms, and in concert with other factors, facilitates a decision by both patients and physicians about the relative benefit of chemotherapy and endocrine therapy. The MammaPrint FFPE 510(k) clearance not only confirmed the robust accuracy, repeatability and reproducibility of the original 70 gene signature, but it also confirmed the clinical performance of the signature using the results of the first ever five-year clinical outcome study (RASTER) in which MammaPrint results were utilized by physicians to decide post-surgical management. In that real-world study, patients were treated according to the best standard of care. Patients with a Low Risk MammaPrint score had a 97.7 % probability of being cancer free at five years, while those with a High Risk score had an 88.5% probability of being cancer free. In a univariate analysis against other clinical pathologic factors, MammaPrint's prognostic value is highly statistically significant (P=0.002).

Similar Private Companies By Industry

Company Name Region
ACS Biomarker B.V. Europe
Agventure Exploitatie BV Europe
Alloksys Life Sciences BV Europe
AM-Pharma B.V. Europe
Amarna Therapeutics B.V. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Agendia N.V., please visit www.agendia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.